158 related articles for article (PubMed ID: 26908614)
1. Mitochondrial targeting of XJB-5-131 attenuates or improves pathophysiology in HdhQ150 animals with well-developed disease phenotypes.
Polyzos A; Holt A; Brown C; Cosme C; Wipf P; Gomez-Marin A; Castro MR; Ayala-Peña S; McMurray CT
Hum Mol Genet; 2016 May; 25(9):1792-802. PubMed ID: 26908614
[TBL] [Abstract][Full Text] [Related]
2. Targeting of XJB-5-131 to mitochondria suppresses oxidative DNA damage and motor decline in a mouse model of Huntington's disease.
Xun Z; Rivera-Sánchez S; Ayala-Peña S; Lim J; Budworth H; Skoda EM; Robbins PD; Niedernhofer LJ; Wipf P; McMurray CT
Cell Rep; 2012 Nov; 2(5):1137-42. PubMed ID: 23122961
[TBL] [Abstract][Full Text] [Related]
3. XJB-5-131-mediated improvement in physiology and behaviour of the R6/2 mouse model of Huntington's disease is age- and sex- dependent.
Polyzos AA; Wood NI; Williams P; Wipf P; Morton AJ; McMurray CT
PLoS One; 2018; 13(4):e0194580. PubMed ID: 29630611
[TBL] [Abstract][Full Text] [Related]
4. XJB-5-131 Is a Mild Uncoupler of Oxidative Phosphorylation.
Xun Z; Wipf P; McMurray CT
J Huntingtons Dis; 2022; 11(2):141-151. PubMed ID: 35404288
[TBL] [Abstract][Full Text] [Related]
5. N-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6/1 mouse model of Huntington's disease.
Wright DJ; Renoir T; Smith ZM; Frazier AE; Francis PS; Thorburn DR; McGee SL; Hannan AJ; Gray LJ
Transl Psychiatry; 2015 Jan; 5(1):e492. PubMed ID: 25562842
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective effects of L-carnitine in a transgenic animal model of Huntington's disease.
Vamos E; Voros K; Vecsei L; Klivenyi P
Biomed Pharmacother; 2010 Apr; 64(4):282-6. PubMed ID: 19932584
[TBL] [Abstract][Full Text] [Related]
7. A Double-Pronged Sword: XJB-5-131 Is a Suppressor of Somatic Instability and Toxicity in Huntington's Disease.
Wipf P; Polyzos AA; McMurray CT
J Huntingtons Dis; 2022; 11(1):3-15. PubMed ID: 34924397
[TBL] [Abstract][Full Text] [Related]
8. Protopanaxtriol protects against 3-nitropropionic acid-induced oxidative stress in a rat model of Huntington's disease.
Gao Y; Chu SF; Li JP; Zhang Z; Yan JQ; Wen ZL; Xia CY; Mou Z; Wang ZZ; He WB; Guo XF; Wei GN; Chen NH
Acta Pharmacol Sin; 2015 Mar; 36(3):311-22. PubMed ID: 25640478
[TBL] [Abstract][Full Text] [Related]
9. Suppression of Somatic Expansion Delays the Onset of Pathophysiology in a Mouse Model of Huntington's Disease.
Budworth H; Harris FR; Williams P; Lee DY; Holt A; Pahnke J; Szczesny B; Acevedo-Torres K; Ayala-Peña S; McMurray CT
PLoS Genet; 2015 Aug; 11(8):e1005267. PubMed ID: 26247199
[TBL] [Abstract][Full Text] [Related]
10. Mitochondrial modulators improve lipid composition and attenuate memory deficits in experimental model of Huntington's disease.
Mehrotra A; Sood A; Sandhir R
Mol Cell Biochem; 2015 Dec; 410(1-2):281-92. PubMed ID: 26374445
[TBL] [Abstract][Full Text] [Related]
11. The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington's disease.
Doria JG; de Souza JM; Andrade JN; Rodrigues HA; Guimaraes IM; Carvalho TG; Guatimosim C; Dobransky T; Ribeiro FM
Neurobiol Dis; 2015 Jan; 73():163-73. PubMed ID: 25160573
[TBL] [Abstract][Full Text] [Related]
12. N-Acetylcysteine reverses mitochondrial dysfunctions and behavioral abnormalities in 3-nitropropionic acid-induced Huntington's disease.
Sandhir R; Sood A; Mehrotra A; Kamboj SS
Neurodegener Dis; 2012; 9(3):145-57. PubMed ID: 22327485
[TBL] [Abstract][Full Text] [Related]
13. Possible neuroprotective effect of Withania somnifera root extract against 3-nitropropionic acid-induced behavioral, biochemical, and mitochondrial dysfunction in an animal model of Huntington's disease.
Kumar P; Kumar A
J Med Food; 2009 Jun; 12(3):591-600. PubMed ID: 19627208
[TBL] [Abstract][Full Text] [Related]
14. Targeting oxidative stress attenuates malonic acid induced Huntington like behavioral and mitochondrial alterations in rats.
Kalonia H; Kumar P; Kumar A
Eur J Pharmacol; 2010 May; 634(1-3):46-52. PubMed ID: 20188726
[TBL] [Abstract][Full Text] [Related]
15. Nortriptyline delays disease onset in models of chronic neurodegeneration.
Wang H; Guan Y; Wang X; Smith K; Cormier K; Zhu S; Stavrovskaya IG; Huo C; Ferrante RJ; Kristal BS; Friedlander RM
Eur J Neurosci; 2007 Aug; 26(3):633-41. PubMed ID: 17686041
[TBL] [Abstract][Full Text] [Related]
16. Increased glutathione levels in cortical and striatal mitochondria of the R6/2 Huntington's disease mouse model.
Choo YS; Mao Z; Johnson GV; Lesort M
Neurosci Lett; 2005 Sep; 386(1):63-8. PubMed ID: 15993538
[TBL] [Abstract][Full Text] [Related]
17. Chrysin exerts neuroprotective effects against 3-Nitropropionic acid induced behavioral despair-Mitochondrial dysfunction and striatal apoptosis via upregulating Bcl-2 gene and downregulating Bax-Bad genes in male wistar rats.
Thangarajan S; Ramachandran S; Krishnamurthy P
Biomed Pharmacother; 2016 Dec; 84():514-525. PubMed ID: 27690136
[TBL] [Abstract][Full Text] [Related]
18. Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.
Wegrzynowicz M; Bichell TJ; Soares BD; Loth MK; McGlothan JS; Mori S; Alikhan FS; Hua K; Coughlin JM; Holt HK; Jetter CS; Pomper MG; Osmand AP; Guilarte TR; Bowman AB
J Huntingtons Dis; 2015; 4(1):17-36. PubMed ID: 26333255
[TBL] [Abstract][Full Text] [Related]
19. Oxidative stress is increased in C. elegans models of Huntington's disease but does not contribute to polyglutamine toxicity phenotypes.
Machiela E; Dues DJ; Senchuk MM; Van Raamsdonk JM
Neurobiol Dis; 2016 Dec; 96():1-11. PubMed ID: 27544481
[TBL] [Abstract][Full Text] [Related]
20. Oral treatment with the herbal formula B401 protects against aging-dependent neurodegeneration by attenuating oxidative stress and apoptosis in the brain of R6/2 mice.
Wang SE; Lin CL; Hsu CH; Sheu SJ; Wu CH
Clin Interv Aging; 2015; 10():1825-37. PubMed ID: 26609226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
